Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...

Guardant Health, Inc. (NASDAQ:GH) is one of the Best Russell 2000 Stocks to Buy Right Now. Wall Street has a positive opinion ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Janux will conduct preclinical studies of the undisclosed program targeting a validated solid tumor antigen expressed across several cancer types.

Morning! Today, we hear that Pfizer CEO Albert Bourla spoke plainly at a WSJ Davos event about his distaste for health ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

Merck & Co unit MSD and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have partnered on a $30 ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

Shares of Moderna ( MRNA +3.94%) popped on Wednesday after the biotech leader announced positive clinical trial results for ...

BofA's US 1 list includes Merck, Apple, Nvidia, Spotify, Goldman Sachs, Walmart, and others, with detailed ratings and sector ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...